All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

NIH Director's Transformative Research Award: Funding Opportunity for Groundbreaking Biomedical Research (R01)

6d ago· 16 min readen

Summary

This is a funding opportunity announcement (FOA) from the NIH for the Director's Transformative Research Award. The award supports individual scientists or groups proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or disrupt current approaches in biomedical research. The document outlines the purpose, eligibility, application requirements, review criteria, and administrative details for this R01-style grant mechanism.

Source

Twitter / XNIH Director's Transformative Research Award: Funding Opportunity for Groundbreaking Biomedical Research (R01)files.simpler.grants.gov

Key quotes

· 3 pulled
The NIH Director's Transformative Research Award supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms.
This award is designed to support research that could potentially create new scientific paradigms, establish entirely new and improved clinical approaches, or disrupt current approaches in biomedical research.
The Transformative Research Award is intended to support exceptionally innovative and/or unconventional research projects that have the potential to create or overturn existing paradigms.
Snippet from the RSS feed
Funding Opportunity Purpose

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.